Protagonist Therapeutics (PGF) Income Statement
Protagonist Therapeutics Income Statement
Last quarter (Q2 2026), Protagonist Therapeutics's total revenue was $213.47M, an increase of 3749.17% from the same quarter last year. In Q2, Protagonist Therapeutics's net income was $162.85M. See Protagonist Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 46.02M | $ 434.43M | $ 60.00M | $ 26.58M | $ 27.36M | |
| $ 44.79M | $ 434.43M | $ 60.00M | $ 26.58M | $ 27.36M | |
| $ 202.92M | $ 181.59M | $ 153.65M | $ 157.95M | $ 153.20M | |
| Depreciation and Amortization | $ 1.28M | $ 2.96M | $ 3.31M | $ 3.37M | $ 2.77M |
| $ -128.03M | $ 282.37M | $ -75.64M | $ -124.02M | $ -122.78M | |
| $ -158.13M | $ 252.84M | $ -93.65M | $ -131.37M | $ -125.84M | |
| $ 28.82M | $ 26.57M | $ 14.70M | $ 3.98M | $ 294.00K | |
| $ -129.31M | $ 279.41M | $ -78.95M | $ -127.39M | $ -125.55M | |
| $ -130.15M | $ 275.19M | $ -78.95M | $ -127.39M | $ -125.55M | |
| Per Share Metrics | |||||
| Basic EPS | $ -2.05 | $ 4.47 | $ -1.39 | $ -2.52 | $ -2.65 |
| Diluted EPS | $ -2.05 | $ 4.23 | $ -1.39 | $ -2.52 | $ -2.65 |
| Weighted Average Shares Outstanding | 63.57M | 61.57M | 56.76M | 49.04M | 46.32M |
| Weighted Average Shares Outstanding (Diluted) | 63.57M | 65.08M | 56.76M | 49.04M | 46.32M |
Currency in USD